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Background: The diagnosis of Rett syndrome (RTT) is based on a set of clinical criteria, irrespective of mutation status.
The aims of this study were (1) to deﬁne the clinical diﬀerences existing between patients with Rett syndrome with (Group I)
and without a MECP2 mutation (Group II), and (2) to characterize the phenotypes associated with the more common
MECP2 mutations. Patients and methods: We analyzed 87 patients fulﬁlling the clinical criteria for RTT. All were observed
and videotaped by the same paediatric neurologist. Seven common mutations were considered separately, and associated clin-
ical features analysed. Results: Comparing Group I and II, we found diﬀerences concerning psychomotor development prior
to onset, acquisition of propositive manipulation and language, and evolving autistic traits. Based on age at observation, we
found diﬀerences in eye pointing, microcephaly, growth, number of stereotypies, rigidity, ataxia and ataxic-rigid gait, and
severity score. Patients with truncating diﬀered from those with missense mutations regarding acquisition of propositive words
and independent gait, before the beginning of the disease, and microcephaly, growth, foot length, dystonia, rigidity and sever-
ity score, at the time of observation. Patients with the R168X mutation had a more severe phenotype, whereas those with0387-7604/$ - see front matter  2010 Elsevier B.V. All rights reserved.
doi:10.1016/j.braindev.2010.01.004
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ARTICLE IN PRESSR133C showed a less severe one. Patients with R294X had a hyperactive behaviour, and those with T158M seemed to be
particularly ataxic and rigid. Conclusion: A clear regressive period (with loss of prehension and language, deceleration of
growth) and the presence of more than three diﬀerent stereotypies, rigidity and ataxic-rigid gait seemed to be very helpful
in diﬀerentiating Group I from Group II.
 2010 Elsevier B.V. All rights reserved.
Keywords: Autism; Mental retardation; Movement disorder; Cerebellum; Clinical criteria; Clinical stage1. Introduction
Rett syndrome (RTT) was ﬁrst described by Andreas
Rett, in 1966 [1], and rediscovered in 1983, by Bent Hag-
berg et al. [2]. Since 1999, after the description of muta-
tions in the MECP2 gene as the cause of RTT [3], we
know that more than 90% of the patients with classical,
but only 30% with variant RTT have a MECP2 muta-
tion. Thus, we can consider two groups of patients:
Group I with clinical features of RTT and a mutation
in the MECP2 gene and Group II with clinical features
of RTT without a mutation in the MECP2 gene, and
speculate that maybe, in addition to Group I patients,
diﬀerent diseases are currently under the large RTT
umbrella. Widespread availability of the molecular diag-
nosis creates a great opportunity for this to be clariﬁed,
based on clinical and genetic grounds.
Several series of patients with genetic studies have
been published, and attempts of phenotype-genotype
correlations made. The results, however, were not con-
clusive, as diﬀerent methodologies were applied in the
various studies, concerning clinical and mutation classi-
ﬁcations and severity score systems [4–6]. Nevertheless,
the larger studies pointed to a broad correlation between
type of mutation and phenotype, patients with truncat-
ing mutations having a more severe phenotype, than
those with missense mutations [5–12].
Two diﬀerent genetic factors are likely to inﬂuence the
phenotype in RTT: the type and location of the muta-
tions, and the X inactivation pattern [13]. Concerning
the phenotype of speciﬁc mutations, several studies
[14–17] showed that patients with the R133C and
R306Cmutations have better overall function. In general,
themost severe outcomeswere foundwith theR270X and
R255Xmutations [11,16].Mutations toward theN termi-
nus, including T158M and R168X, were also associated
with amore severe phenotype [12,17]; however, no speciﬁc
neurological or behavioural ﬁndings were identiﬁed in
patients with these mutations, with the exception of an
association of fear and anxiety with R133C and R306C
[18], andmood abnormalities in patientswithR294X [16].
The aims of this study were (1) to deﬁne the clinical
diﬀerences between patients with (Group I) and without
(Group II) known mutations in the MECP2 gene, in
order to delineate the clinical boundaries of the disease;
(2) to analyze the genotype-phenotype correlation inPlease cite this article in press as: Temudo T et al. Rett syndrome with an
notypes. Brain Dev (2010), doi:10.1016/j.braindev.2010.01.004Group I patients and characterize phenotypes associated
with the more common MECP2 mutations; and (3) to
identify sub-groups of patients with RTT that might
be candidates for mutational search in other genes.
2. Subjects and methods
All Portuguese paediatric neurologists were asked to
indicate their patients with possible RTT. Patients
included in the study (n = 87) fulﬁlled the revised clinical
criteria for RTT [19]. They were observed and video-
taped by the same paediatric neurologist (TT), and a
clinical checklist for RTT was completed. Informed con-
sent was obtained from all parents, for blood sampling
and to take and use videos and photographs; 36 patients
were observed and videotaped at least twice, at 6 months
intervals.
Blood samples from patients and their parents were
received at the laboratory, and genomic DNA was
extracted using the Puregene DNA isolation kit (Gentra,
Minneapolis, MN). The coding region and exon–intron
boundaries of the MECP2 gene were ampliﬁed by PCR
and sequenced. The RD-PCR method was used, as
described [20], for the detection of large rearrangements
in the MECP2 gene. Primers and PCR conditions are
available upon request.
X-chromosome inactivation (XCI) assays were per-
formed with genomic DNA isolated from leukocytes of
peripheral blood. The assay was based on a previously
described method [21], which allows the determination
of the X-inactivation status, using a trinucleotide repeat
polymorphism in the androgen receptor gene (AR, Ref-
Seq ID: NM_000044.2), ﬂanked by two methylation-sen-
sitive restriction enzyme sites. The restriction enzyme
(HhaI) will hydrolyze only the unmethylated alleles.
Scoring of the XCI pattern was made by densitometry
of the ampliﬁed DNA bands.
MECP2 mutations were categorized and grouped for
analysis according to: (1) type of sequence change – mis-
sense or truncating (including nonsense and frameshift,
but also large deletions) and (2) location of the mutation
(aﬀected domain) – TRD, MBD. The seven most com-
mon mutations were considered individually, and their
associated features analysed.
For statistical analysis, patients were divided into two
groups: those with (Group I) and without a moleculard without detected MECP2 mutations: An attempt to redeﬁne phe-
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group, comparisons were made between patients carry-
ing missense and truncating mutations. Cases were
scored using the Pineda severity scale [6]. The SPSS
(v.14) statistical package was used to analyse the data.
Proportions were compared using Chi-square and Fish-
er’s exact test. Quantitative variables were compared
using the Mann–Whitney test and were presented as
median (25–75th percentile).
3. Results
In this study we analyzed the entire coding sequence
of the MECP2 gene in 87 patients, who fulﬁlled the
revised clinical criteria for RTT [19]. Cases were classi-
ﬁed as classical (58.6%) and variant (41.4%) forms (con-
genital, preserved speech, forme fruste, early epileptic
encephalopathy and male patients) [22].
3.1. Clinical diﬀerences between MECP2 positive and
negative RTT patients
Mutations in MECP2 were found in 67.8% (n = 59)
of all patients, corresponding to 96.0% of classical forms
and of 27.8% variants (seven congenital forms; three
preserved speech). In 28 patients MECP2 mutations
were not found. Among these patients 60.7% were
congenital, 10.7% males, 10.7% early epileptic encephal-
opaties, 7.1% classical, 7.1% forme frustre and 3.6% pre-
served speech forms.
We identiﬁed a total of 29 diﬀerent mutations in
MECP2 including two large deletions and a mutation in
exon 1; most mutations were located in exons 3 and 4
(Fig. 1). Nine of these mutations were never described
before: A7fsX37, K39fsX43, Q110X, S113P, T184fsXFig. 1. Diﬀerent mutations found in MEC
Please cite this article in press as: Temudo T et al. Rett syndrome with an
notypes. Brain Dev (2010), doi:10.1016/j.braindev.2010.01.004185, R253fsX275, I303fsX399, V380M and L386fsX
399. All were de novo mutations, except V380M which
was present in the unaﬀectedmother (who had a balanced
XCI pattern) and in 4 X chromosomes in a control popu-
lation of Portuguese origin including 230 X chromo-
somes. We assumed the truncating mutations as
causative of the disease; the new missense mutation
S113P was excluded in the parents and in a control
population of Portuguese origin including 230 X
chromosomes.
XCI patterns were analysed for all patients carrying a
MECP2 mutation, though data was not informative for
14; among the 46 patients remaining, only two showed a
skewed XCI pattern. Of these, one patient with a R168X
mutation had a less severe form (and a lower severity
score) compared with the group of patients with the
same mutation: she acquired and maintains independent
gait, had neither epilepsy nor microcephaly. The other
patient carried the T158M mutation, and had a pheno-
type similar to those carrying the same mutation. Med-
ian age at ﬁrst observation and median duration of the
disease were not signiﬁcantly diﬀerent between Group
I and II, neither between groups with missense and trun-
cating mutations. A signiﬁcant diﬀerence was found
when comparing clinical stage: more patients with
Group I, especially those with truncating mutations,
were in stage IV of the disease, which may mean that
their rate of evolution was faster.
Comparison between Group I and II showed some
important clinical diﬀerences since birth (Table 1).
Dystocic delivery (caesarean or forceps) seemed to
be more common in Group I than Group II patients,
though this did not reach signiﬁcance. Additionally,
none of the Group II patients presented microcephaly
at birth, but 6 (10.2%) of Group I had an occipito-P2 in 87 Portuguese RTT patients.
d without detected MECP2 mutations: An attempt to redeﬁne phe-
Table 1
Clinical data of Group I and Group II patients.
Group I (n = 59) Group II (n = 28) p Missense (n = 26) Truncanting (n = 33) p
Median age (years)a 7.6 (4.1–14.3) 7.8 (5.1–12.7) 0.730 7.0 (3.7–10.6) 11.3 (4.5–14.8) 0.27 5
Median duration of disease (months)a 92 (55–140) 82 (35–139) 0.411 72 (26–111) 124 (44–157) 0.240
Stage (%)
Stage II
Stage III
Stage IV A and IV B
8.5
61.0
30.5
3.6
82.1
14.3
0.153 7.7
80.8
11.5
9.0
45.5
45.5
0.008
Perinatal data (%)
Abnormal delivery 28.8 21.4 0.466 23.1 33.3 0.566
Microcephaly at birth
Yes
Missing information
10.2
16.9
0.0
21.4
0.263 11.5
15.4
9.1
18.2
0.999
Reported psychomotor development (%)
Normal until 12 months of age 59.3 17.9 <0.001 69.2 51.5 0.268
Stagnation 93.2 92.9 0.999 92.3 93.9 0.999
Median age of stagnation (months)a 12.0 (10.0–18.0) 6.0 (4.0–11.3) <0.001 16.0 (10.0–18.0) 12.0 (9.0–18.0) 0.172
Regression 86.4 25.0 <0.001 84.6 87.9 0.999
Median age of regression (months)a 18.00 (14.0–24.0) 14.00 (11.0–24.0) 0.202 18.0 (18.0–24.5) 18.0 (13.0–23.0) 0.160
Acquisition of autistic traits 83.1 50.0 0.002 76.9 87.9 0.222
Median age of acquisition of autistic traits 18.0 (12.5–18.0) 7.5 (3.75–18.0) 0.005 18.0 (14.0–21.0) 15.0 (12.0–18.0) 0.175
Propositive manipulation 91.5 57.1 <0.001 92.3 93.8 0.999
Median age of acquisition of stereotypies 20.0 (14.5–25.0) 24.0 (14.5–36.0) 0.425 24.0 (18.0–28.5) 18.00 (13.3–24.0) 0.086
Propositive words 71.2 17.9 <0.001 88.5 57.6 0.021
Acquisition of independent gait 63.3 50.00 0.200 84.6 48.5 0.009
Data at observation
Eye pointing 96.6 57.1 <0.001 92.3 100.0 0.190
Mycrocephaly at time of observation 45.8 39.3 0.569 19.2 66.7 0.001
Low weight (<5th percentile) 43.3 18.5 0.031 23.1 57.6 0.009
Low height (<5th percentile) 55.2 30.8 0.038 38.5 68.8 0.033
Low foot length (<3th percentile) 67.9 45.8 0.112 47.8 83.3 0.008
Agitation 56.7 67.9 0.497 50.0 63.6 0.426
Laughing spells 69.5 53.6 0.227 61.5 75.8 0.372
Abnormal sleep pattern 55.9 53.6 0.836 46.2 63.6 0.199
Hyperpnea/Apnea 78.0 82.1 0.868 69.2 84.8 0.209
Epilepsy 57.6 75.0 0.183 46.2 66.7 0.184
Controlled 58.8 76.2 0.306 69.2 52.4 0.477
Vaso-motor disturbances 71.2 78.6 0.639 53.8 84.8 0.019
Neurogenic muscle atrophy 49.2 28.6 0.114 42.3 54.5 0.435
Chewing diﬃculties 78.0 71.4 0.691 65.4 87.9 0.080
Pyramidal signs 28.8 39.3 0.3465 23.1 33.3 0.566
Ataxia 35.6 10.7 0.030 46.2 27.3 0.219
Number of stereotypies per patienta 4.00 (3.0–6.0) 3.00 (2.2–4.0) 0.050 3.50 (2.8–7.0) 4.00 (3.0–6.0) 0.999
Dystonia 64.6 75.0 0.458 46.2 78.8 0.0209
Rigidity 49.2 7.1 <0.001 34.6 60.6 0.046
Tremor 49.2 35.7 0.344 50.0 48.5 0.999
Ataxic/rigid gait 43.6 0.0 0.001 36.8 50.0 0.523
Scoliosis 72.9 67.9 0.818 69.2 75.8 0.791
Gastro–intestinal (%)
Gastro-esophageal reﬂux 11.9 14.3 0.999 11.5 12.1 0.999
Pineda’s scalea 13 (9–15) 14 (12–16) 0.034 11 (8–13) 14 (11–16) 0.001
a Data presented as median (25–75th percentile).
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ARTICLE IN PRESSfrontal circumpherence (OFC) below the 5th percentile
(3 truncating, 3 missense mutations). Also, 63.6% of
Group II patients presented an OFC at birth above
the 25th percentile, against 26.6% of Group I patients.
Stagnation of OFC growth occurred in 71.7% of
Group I and 53.6% of Group II, at a median age
of 6 months in both groups. Later, microcephaly wasPlease cite this article in press as: Temudo T et al. Rett syndrome with an
notypes. Brain Dev (2010), doi:10.1016/j.braindev.2010.01.004acquired in 45.8% of Group I (67.6% among truncat-
ing, 19.2% for missense mutations) and 39.3% of
Group II patients. Interestingly, 13.3% of Group I
patients presented an OFC above the 25th percentile
(3% above the 75th percentile); 26.9% of patients with
missense mutations presented an OFC above the 25th
percentile, against only 2.9% of those with truncatingd without detected MECP2 mutations: An attempt to redeﬁne phe-
Fig. 2. Frequency of missense versus truncating mutations according
to the three clinical subtypes.
T. Temudo et al. / Brain & Development xxx (2010) xxx–xxx 5
ARTICLE IN PRESSmutations. Diﬀerences were also found for height and
weight, comparing the two groups, and for head size,
height, weight and foot length, comparing the group
of patients with missense versus truncating mutations
(Table 1).
Clinical classiﬁcation in these groups was also diﬀer-
ent: 83.0% of Group I were classiﬁed as classical, against
only 7.1% of Group II patients. Signiﬁcant diﬀerences
were found when comparing psychomotor development
before the onset of the disease: in a higher percentage of
Group II patients, this was not considered to be normal,
by the parents, before the age of 12 months; a clear
regression period was evident in 86.4% of Group I,
but only 25.0% of Group II patients; acquisition of pro-
positive words was more common in patients with
Group I, specially those with missense mutations; evolv-
ing of autistic traits (loss of social communication) was
described in 83.1% of Group I and 50% of Group II, and
it occurred earlier in life in Group II; in 42.9% of Group
II, propositive manipulation was never acquired (against
8.5% in Group I); independent gait was acquired by
84.6% of patients with missense, but only in 48.5% of
those with truncating mutations (Table 1).
Besides growth failure, we found other important dif-
ferences concerning clinical data of the patients at obser-
vation: eye pointing was present in 96.6% of Group I, but
only in 57% of Group II patients; rigidity and ataxia were
more frequent in Group I, and an ataxic-rigid gait was
observed only in them.They also displayed a greater num-
ber of stereotypies. Dystonia, rigidity, vaso-motor distur-
bances and oral motor diﬃculties were more frequent in
patients with truncating mutations (Table 1). We found
no signiﬁcant diﬀerences between the group I and II con-
cerning pyramidal signs, dystonia, neurogenic muscle
atrophy, vaso-motor disturbances, scoliosis, epilepsy or
gastro-intestinal disturbances. Abnormal sleep pattern,
agitation, laughing spells and hyperpnea/apnea were also
not more frequent in patients with known mutations.
The Pineda’s severity score showed that the median
severity was greater in the Group I group and, within
this group, in those with truncating mutations (Table 1).
3.2. Clinical presentation among MECP2 positive RTT
patients (group i)
In general, we identiﬁed three neurological presenta-
tions in Group I patients:
(1) Some had a severe form (n = 27; 45,8% of all Group I
patients), with major axial hypotonia, in which dystonia
and rigidity were present after few years of evolution
(median, 11 years). These patients either regressed earlier
(median, 15.0; range, 6–36 months), or never had been
normal (18.5%); 74.0% did not acquire independent gait;
those who did, lost it at amedian age of 66 months (range,
24–120). Epilepsy was present in 70.4% of the cases.
Among patients with the severe form, 81,4% had truncat-Please cite this article in press as: Temudo T et al. Rett syndrome with an
notypes. Brain Dev (2010), doi:10.1016/j.braindev.2010.01.004ing mutations, and all but one with the R168X mutation
presented it; they showed a median severity score of 15
(range, 12–20).
(2) In an intermediate form, ataxia predominated
(n = 17; 28.8% of all Group I patients). Most acquired
an independent gait (94.1%), but this was both ataxic
and rigid; they regressed at a median age of 18 months
(13–26), and 52.9% had epilepsy. Their median severity
score was 11 (range, 8–14); 68.8% of the patients with
this presentation had missense mutations, particularly
T158M.
(3) A milder form was present in 15 (25,4%) of Group
I patients, with few neurological signs except for mental
retardation and autistic features. All acquired indepen-
dent gait and maintained it during the period of fol-
low-up; 40% developed focal dystonia after some years
of evolution, and gait became rigid in two patients
(one with the R133C mutation, older than 20 years;
one six years old with the R294X mutation). Epilepsy
was present in 33.3% of these patients. They regressed
at a median age of 25 months (range, 13–60), and had
a median severity score of 9 (range, 4–11); 60% had mis-
sense mutations. Most of our patients with the R133C
mutation illustrate this presentation well. Three patients
with R294X mutation also presented this phenotype.
Interestingly, the distribution of mutation types was
signiﬁcantly diﬀerent between these clinical groups. In
the milder group, 60% of the patients had missense
mutations. In the intermediate group, 70,6% of the
patients had missense mutations; and in the more severe
group 81.5% of the cases had a truncating mutation. The
frequency of missense versus truncating mutations was
signiﬁcantly diﬀerent between the three clinical subtypes
(Fisher’s exact test, p = 0.001) (Fig. 2).
3.3. Clinical presentation associated with speciﬁcMECP2
mutations
The clinical features associated with speciﬁc muta-
tion groups found in Group I patients are presented ind without detected MECP2 mutations: An attempt to redeﬁne phe-
T
ab
le
2
C
li
n
ic
al
ch
ar
ac
te
ri
st
ic
s
o
f
p
at
ie
n
ts
w
it
h
th
e
se
ve
n
m
o
st
fr
eq
u
en
t
m
u
ta
ti
o
n
s.
R
16
8X
n
=
9
T
15
8M
n
=
8
R
13
3C
n
=
6
R
29
4X
n
=
4
R
27
0X
n
=
3
R
10
6W
n
=
3
R
25
5X
n
=
3
M
ed
ia
n
ag
e
(y
ea
rs
)a
(
ra
n
g
e)
11
(2
–2
3)
6
(
1
–
1
6
)
7
(5
–3
1)
6.
5
(5
–1
1)
7
(2
–2
4)
7
(3
–7
)
15
(2
–2
1)
M
ed
ia
n
ag
e
o
f
re
gr
es
si
o
n
(m
o
n
th
s)
a
(
ra
n
g
e)
12
(6
–2
3)
18
(1
4–
27
)
34
(1
8–
60
)
33
(1
8–
36
)
14
(1
3–
21
)
18
(a
ll
18
)
15
(1
3–
28
)
C
li
n
ic
al
cl
as
si
ﬁ
ca
ti
o
n
8
cl
as
si
ca
l
1
co
-n
at
al
8
cl
as
si
ca
l
3
cl
as
si
ca
l
3
P
S
4
cl
as
si
ca
l
3
cl
as
si
ca
l
3
cl
as
si
ca
l
3
cl
as
si
ca
l
M
ic
ro
ce
p
h
al
y
(%
)
66
.6
25
0.
0
50
66
.6
66
.6
33
.3
L
o
w
w
ei
gh
t
(%
)
77
.7
37
.5
16
.6
25
33
.3
0.
0
66
.6
L
o
w
h
ei
gh
t
(%
)
66
.6
50
50
25
66
.6
33
.3
66
.6
A
cq
u
is
it
io
n
o
f
in
d
ep
en
d
en
t
ga
it
(%
)
22
.2
*
87
.5
*
10
0*
10
0*
66
.6
33
.3
33
.3
In
d
ep
en
d
en
t
at
ax
ic
-r
ig
id
ga
it
(n
)
1/
2
5/
7
1/
5
2/
4
0/
2
0/
1
1/
1
A
b
il
it
y
to
sp
ea
k
(%
)
0.
0
0.
0
50
0.
0
0.
0
0.
0
0.
0
P
ro
p
o
si
ti
ve
p
re
h
en
si
o
n
(%
)
11
50
83
.3
75
33
.3
33
.3
33
.3
N
o
.
o
f
st
er
eo
ty
p
ie
sa
3
(2
–8
)
4.
50
(2
–1
1)
3
(2
–1
0)
9.
50
(5
–1
2)
3
(9
–3
)
3
(3
–4
)
3
(3
–4
)
M
o
to
r
ag
it
at
io
n
(%
)
0.
0
37
.5
50
10
0*
*
66
.6
66
.6
66
.6
H
P
P
/A
p
n
o
ea
(%
)
88
.8
75
66
.6
10
0
66
.6
66
.6
66
.6
R
ig
id
it
y
(%
)
66
.6
62
.5
16
.6
10
0
33
.3
33
.3
33
.3
E
p
il
ep
sy
(%
)
66
.6
37
.5
16
.6
10
0
66
.6
66
.6
33
.3
S
co
li
o
si
s
o
r
k
yp
h
o
si
s
(%
)
77
.7
62
.5
66
.6
50
66
.6
66
.6
66
.6
S
co
re
in
P
in
ed
a’
s
sc
al
ea
16
(9
–1
9)
11
(7
–1
4)
7.
5
(4
–1
1)
10
(8
–1
3)
11
(1
0–
16
)
13
(8
–1
5)
12
(1
1–
14
)
P
S
,
p
re
se
rv
ed
sp
ee
ch
.
*
O
n
e
p
at
ie
n
t
lo
st
in
d
ep
en
d
en
t
ga
it
,
1
ye
ar
af
te
r
ac
q
u
is
it
io
n
.
*
*
V
er
y
ag
it
at
ed
.
a
D
at
a
p
re
se
n
te
d
as
m
ed
ia
n
(2
5–
75
th
p
er
ce
n
ti
le
).
6 T. Temudo et al. / Brain & Development xxx (2010) xxx–xxx
ARTICLE IN PRESSTable 2. Overall, we observed that those with the
R168X mutation presented the most severe phenotype.
Only two of nine patients with this mutation acquired
independent gait; one lost it one year later, while the
other had a very rigid and ataxic gait. Two presented
microcephaly at birth and six developed it within the
2nd year of life. The majority had low height and
weight, and epilepsy. They also had continuous
hands-apart stereotypies.
Group I patients with the R294X mutation seemed to
have a peculiar phenotype with an extremely unusual
hyperactive motor behaviour. They had a lot of diﬀerent
and exuberant hand stereotypies and with other topog-
raphies (including vocal), and all had epilepsy. All dis-
played focal or segmental dystonia, and, in three, gait
became rigid and broaded based, in the earlier stages
of the disease; however, they maintained a good eye con-
tact, and seemed less profoundly retarded than other
patients with better motor function.
Patients with the R133C mutation had the mildest
phenotype among all those within the Group I. None
had microcephaly, and all but one acquired and main-
tained independent gait. Three could make phrases,
albeit with a peculiar voice tone, and answered to simple
questions, after a considerable delay of time. Also, only
one had epilepsy (the same patient who lost independent
gait), and ﬁve maintained propositive prehension (three
fed themselves with a spoon).
Some particular clinical features were also found in
patients with the T158M mutation; the majority could
walk without support, but their gait tended to be very
rigid and ataxic, since the beginning of the disease; pos-
tural and intention tremor was evident, and they had
many diﬀerent stereotypies.
4. Discussion
4.1. Clinical features: redeﬁning MECP2 positive and
negative RTT
The diagnosis of Rett syndrome remains clinical, and
this may lead clinicians to decide whether or not, to
request a laborious MECP2 mutation screening. Both
from a scientiﬁc and economic point of view, it is very
important to deﬁne more restrictive criteria, to improve
the rate of ﬁnding a MECP2 mutation, and to identify
groups of patients that may have a diﬀerent disease.
Comparing patients with and without a MECP2
mutation (Group I and Group II), we concluded that
there are signiﬁcant clinical diﬀerences between them.
Among Group II patients, only a minority had a normal
development during the ﬁrst year of life, and a regressive
period was not evident to their parents; also, autistic
behaviour, when noticed, occurred very early in life,
which means that these children may never have been
normal.Please cite this article in press as: Temudo T et al. Rett syndrome with and without detected MECP2 mutations: An attempt to redeﬁne phe-
notypes. Brain Dev (2010), doi:10.1016/j.braindev.2010.01.004
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ARTICLE IN PRESSPropositive manipulation was acquired in the vast
majority of Group I, but less frequently in Group II
patients. On the whole, we observed that patients with
no detected MECP2 mutation had worse social contact
and less stereotypies. Our results suggest that eye point-
ing seems to be an important sign to suspect for Group
I. Rigidity, and especially the presence of an ataxic-rigid
gait, seems to be very speciﬁc of Group I: none of the
patients without a MECP2 mutation presented it.
Growth failure was also more evident in the group with
detected mutations. Surprisingly, hyperpnea/apnea were
not more frequent in patients with known mutations,
which suggests that this sign is not particularly helpful
to diﬀerentiate group I from group II patients.
4.2. Genotype-phenotype correlations in MECP2 positive
RTT
At a comparable age of observation, patients with
truncating mutations had a higher probability of dis-
playing microcephaly, as well as low weight, low height,
small foot length and dystonia. Rigidity and oral motor
diﬃculties, albeit not signiﬁcant, were also more fre-
quent in the group of patients with truncating muta-
tions. Overall, the mean severity score of the patients
with truncating mutations was higher, and these patients
were more likely to display a severest than a milder or
intermediate phenotype as was already described by
other authors [11–16].
Regarding the most common MECP2 mutations in
our series, patients with the R294X mutation seemed
to have an extremely unusual hyperactive motor behav-
iour. They had many diﬀerent stereotypies, and all had
epilepsy. Robertson et al. [18] described also that
patients with this mutation were more likely to have
mood diﬃculties, but they did not report hyperactive
motor behaviour; they also reported that hand stereoty-
pies were less frequent in these patients, which is in con-
tradiction with our data.
Ambulant Group I patients may have a normal gait
for decades, mainly those with less severe mutations,
as is the case of R133C; however, the majority of ambu-
lant patients have a particular wide-based and rigid gait,
unique of this disease. Bradykinesia and rigidity appear
at diﬀerent times of evolution, some patients presenting
these neurological signs very early in life. As we showed
in previous work, stereotypies other than those with the
hands tend to disappear, and even hand stereotypies slo-
wed down with age, which may reﬂect the neurochemi-
cal evolution of this complex disease [23].
In Group I patients, motor disability was not neces-
sarily correlated with severity of the behavioural pheno-
type or mental impairment. In our sample, some girls
who never acquired independent gait had a good social
contact and seemed to be calmer than others with very
good motor function.Please cite this article in press as: Temudo T et al. Rett syndrome with an
notypes. Brain Dev (2010), doi:10.1016/j.braindev.2010.01.0044.3. MECP2 positive RTT: explaining the symptom
clusters
It is not clear why diﬀerent MECP2 mutations can
produce a particular phenotype, but one hypothesis is
that some CNS areas are more susceptible than others
to the degree of dysfunction of this protein.
The diﬀerent timing of disease onset among patients
with a MECP2 mutation and the diﬀerent neurological
pictures – previously recognized by others, but with a
diﬀerent classiﬁcation [24] – may be partially explained
by the preferential function of MECP2 in mature, rather
than immature neurons [25]. One could speculate that a
less functional protein may aﬀect more dramatically the
brainstem and cerebellar structures, provoking, for
instance, such a severe hypotonia that patients can never
acquire an independent gait. On the other hand, a more
functional (or less disruptive) protein may not aﬀect so
severely the cerebellar structures, but absence of its full
functionality may still be critical for the cortical function
and, thus, provoke a milder phenotype where mental
retardation predominates. In the human brain, although
the number of MeCP2-expressing neurons increases dra-
matically throughout gestation, the percentage of neu-
rons expressing MeCP2 in the cortex continues to
increase from birth to age 10 years [25]. This may also
contribute to explain the progressive features of this
disorder.
5. Final remarks
Some important questions remain, nevertheless: why
are some classical forms of RTT not associated with
MECP2 mutations? How do diﬀerent gene mutations
produce a similar phenotype? Detailed analysis of larger
series of mutation-negative RTT patients may help
deﬁne clinically homogeneous sub-groups that are good
candidates for the search of mutations in other genes.
Disclosure
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